Slide 1: Financial Results Half Year Ended 30 June 2023
Financial Results Half Year Ended 30 June 2023
Slide 2: Vita Life Sciences Ltd
Vita Life Sciences Ltd Vita Life Sciences is an Australian owned healthcare company that is listed on the Australian Securities Exchange (ASX:VLS). Our core business is the development and Values Vita Life Sciences has a distribution of over the counter (OTC) medicines, as companywide commitment to:
Slide 3: Commentary
Commentary GROUP SALES GROUP EBIT A$’m A$’m Half Year Half Year
Slide 4: Australia
Australia Revenue of $21.1m an increase of 14% on PCP. A$’m Revenue up 14% A$’m EBIT up 29% New customer acquisition across the Pharmacy channel continues with market share gains reported across the category. Consumer offtake domestically was particularly strong in conjunction with a mass medi
Slide 5: Malaysia
Malaysia Revenue of $9.9m a decrease of 3% on PCP. A$’m Revenue down 3% A$’m EBIT down 20% Malaysian market showcased resilience amongst tougher trading conditions. The business deployed a strategy to increase the VitaHealth brands footprint across many chain pharmacies. Increase trade marke
Slide 6: Singapore
Singapore Revenue of $2.9m a marginal 5% increase on PCP. A$’m Revenue up 5% A$’m EBIT down to small loss Increased product ranging into “modern trade” retailers supported the improved performance Increased ranging of the VitaHealth range across modern trade Pharmacies, resulted in higher adve
Slide 7: Other Asia
Other Asia Revenue of $0.8m a decrease of 38% on PCP The Vietnam market conditions have been impacted by slower economic trading conditions. The conditions experienced in the H1 are expected to continue for the remainder of the year. Herbs of Gold Vietnam market launch expected in Q4 F23. Di
Slide 8: Interim Dividend & Cashflows
Interim Dividend & Cashflows Gross operating cashflow to EBITDA Interim dividend per share Operating cashflow conversion improved due to higher sales and reduction in stock holding levels following 120% normalisation of manufacturing lead times from 100% suppliers in selective markets. 80% Fully
Slide 9: Priorities & Outlook
Priorities & Outlook Guidance will be provided in the 4th quarter 2023
Slide 10: Appendix
Appendix WAVITA LIFE
Slide 11: Half Year Results
Half Year Results 2023 2022 Half year ended June $’m $’m Revenue 34.7 32.7 EBITDA 5.7 5.5 EBIT 5.4 5.3 Profit before tax 5.5 5.3 Profit after tax 4.0 3.6 EPS (Basic – cents/ share) 7.42 6.89 Dividend (cents / share) 3.00 2.75
Slide 12: Balance Sheet
Balance Sheet Jun 2023 Dec 2022 Balance Sheet as at $’m $’m Current assets 44.1 41.2 Non-current assets 10.2 10.6 Total assets 54.2 51.8 Current liabilities 14.7 14.9 Non-current liabilities 0.3 0.4 Total Liabilities 15.0 15.3 Net Assets 39.2 36.5
Slide 13: Cash Flow
Cash Flow 2023 2022 Cash Flow for the half year ended June $’m $’m Receipts from customers 35.3 32.5 Payments to suppliers and employees (29.3) (30.8) Gross operating cash flow 6.0 1.7 EBITDA 5.7 5.5 Gross operating cash flow / EBITDA 105% 31% Net interest 0.1 (0.0) Income tax paid (1.5) (1.7) Opera
Slide 14: 1/ Bath Road, Kirrawee, NSW 2232
© +612 9545 2633 1/ 102 Bath Road, Kirrawee, NSW 2232 / ’ Cy enquiries@vitalifesciences.com.au —S ANDREW O’KEEFE CHIN LKHOO @ vitalifesciences.com MANAGING DIRECTOR CHIEF FINANCIAL OFFICER
Slide 15: Disclaimer
Disclaimer This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences or VLS) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitati